newsfilter
← Latest News
GlobeNewswire·

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

  • Kyverna Therapeutics CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on November 17, 2025 at 1:00 p.m. GMT.
  • A live webcast of the presentation will be accessible via the Investors section of the Kyverna website at ir.kyvernatx.com.
  • A replay of the webcast will remain available on the website for approximately 90 days after the conference.
  • Kyverna's lead candidate KYV-101 is in late-stage development with registrational trials for stiff person syndrome & myasthenia gravis.
  • Two ongoing multi-center Phase 1/2 trials for KYV-101 are currently evaluating patients with lupus nephritis.
  • The company is exploring next priority indications for KYV-101 through KYSA trials & investigator-initiated trials in multiple sclerosis & rheumatoid arthritis.
  • Kyverna's pipeline includes next-generation CAR T-cell therapies in autologous & allogeneic formats, including the potential to expand patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process.